Guideline Highlights:<\/p>\n
\n\tThe first clinical practice guideline on acute pulmonary embolism (PE) from the American Heart Association and the American College of Cardiology introduces a new Acute Pulmonary Embolism Clinical Category system to define the severity of an acute pulmonary embolism and assist in developing a treatment strategy for adults with this condition.
\n\tThe guideline details risk factors for acute PE, such as recent surgery or hospitalization, trauma, prolonged immobility, pregnancy, obesity, cancer and blood clotting disorders, among others.
\n\tComprehensive recommendations are included for diagnostic strategies and treatment options to improve outcomes for patients with acute PE, depending on the care setting\u2014emergency department, inpatient setting or outpatient clinic\u2014and availability of local resources.
\n\tGuidance is also provided on follow-up care after acute PE diagnosis and treatment, including safe physical activity, travel considerations and long-term use of anti-clotting medications.
<\/p>\n
Embargoed until 1:00 p.m. CT\/2:00 p.m. ET Thursday, Feb. 19, 2026<\/p>\n
DALLAS and WASHINGTON, Feb. 19, 2026 \u2014 Early detection and prompt treatment of acute pulmonary embolism (PE), a sudden and potentially life-threatening blood clot that blocks arteries in the lungs, is critical. Comprehensive recommendations for the evaluation, management and follow-up care for adults with acute PE are detailed in this new clinical practice guideline, published today in the American Heart Association\u2019s flagship peer-reviewed journal Circulation and in JACC, the flagship journal of the American College of Cardiology.<\/p>\n
A PE is a blood clot that typically originates in a deep vein in the leg or pelvis, travels through the heart and becomes lodged in an artery in the lungs. It is part of a condition known as venous thromboembolism<\/a> (VTE). Acute PE can lower oxygen levels in the blood, damage lung tissue and put serious strain on the heart, making it a potentially fatal medical emergency. According to the American Heart Association\u2019s 2026 Heart Disease and Stroke Statistics<\/a>, approximately 470,000 people are hospitalized with PE in the U.S. annually, and approximately 1 in 5 high-risk patients die.\u00a0<\/p>\n \u201cThere have been significant advances in the understanding of pulmonary embolism and treatments to effectively manage this condition,\u201d said Chair of the guideline writing committee Mark A. Creager, M.D, FAHA, FACC, a professor of medicine at the Geisel School of Medicine at Dartmouth College in Hanover New Hampshire, and director emeritus of the Heart and Vascular Center at Dartmouth Health in Lebanon, New Hampshire. \u201cThis guideline is a road map to help clinicians navigate these advances for the safest and most effective approaches to care for people with this condition\u201d he said.<\/p>\n The new guideline includes patient treatment recommendations by care setting, including which patients can be discharged from the emergency department and managed as outpatients; which patients require hospitalization; and which patients need critical care. It also acknowledges that implementation of the recommendations depends on the availability of local resources, such as specialists for consultations, imaging tests and advanced interventions.\u00a0<\/p>\n New clinical classification system<\/p>\n New Acute PE Clinical Categories are introduced to classify patients with acute PE into five categories (A-E), based on their severity of symptoms and risk for adverse outcomes. Patients in Categories A and B have no or mild symptoms and low risk of experiencing severe complications; they often can be safely discharged from the emergency department. Categories C-E include people with symptoms of acute PE who are at higher risk of adverse outcomes and require hospitalization (chart available under resources)<\/a>.<\/p>\n Risk factors associated with acute PE<\/p>\n Prompt diagnosis of acute PE is essential for timely treatment, which can prevent severe complications such as cardiac arrest and death. However, timely diagnosis of acute PE is often challenging because many symptoms, such as shortness of breath, chest pain, rapid heartbeat, fainting and\/or dizziness, are similar to symptoms for of other conditions.<\/p>\n Factors that damage the veins or reduce blood flow, or conditions that promote the likelihood of clot formation, can increase the risk of VTE. When considering the probability of acute PE, clinicians should assess patients for factors that increase the risk for clotting, including:<\/p>\n
Laboratory and diagnostic testing <\/p>\n In patients who have a low or intermediate probability (<50%) of acute PE based on symptoms, risk factor assessment and physical examination, a blood test should be obtained to measure D-dimer, a protein fragment released into the blood when the body breaks down a clot. Patients with normal levels of D-dimer are unlikely to have a pulmonary embolism. If the D-dimer level is elevated, or if the clinical probability of acute PE is deemed high (>50%), imaging to look for a PE is recommended.<\/p>\n Computed tomography pulmonary angiography (CTPA) is the standard imaging test to diagnose or rule out acute PE. It is highly accurate, stand-alone imaging to find and visualize the location and size of the blood clot, and is widely available in emergency rooms across the country. People who cannot undergo CTPA (for example, patients with an allergy or reaction to iodine-based contrast dye) should be screened for acute PE with a lung ventilation\/perfusion scan (a type of nuclear imaging test).\u00a0<\/p>\n Treatment strategies<\/p>\n Anticoagulants<\/a> (medications that prevent blood clots from forming) are the primary treatment recommended for patients with confirmed acute PE. Direct oral anticoagulants (DOACs), such as rivaroxaban, apixaban, edoxaban or dabigatran, are recommended over vitamin K antagonists, such as warfarin, to prevent recur\u00adrent blood clots, due to their safety, ease of use and reduced risk of major bleeding. DOACs are not recommended during pregnancy due to potential risks to the fetus. Low-molecular-weight heparin or unfractionated heparin can be safely used for acute PE during pregnancy.<\/p>\n Patients with acute PE in Categories D-E may need advanced treatments and procedures, including intravenous or catheter-based administration of a clot dissolving drug, catheter-based mechanical removal of the blood clot(s) or surgical removal of the blood clot(s). The guideline also details appropriate sedation, venti\u00adlation and mechanical circulatory support to maintain heart and lung function for critically ill patients with acute PE.<\/p>\n Considerations for follow-up management<\/p>\n Follow-up communication and clinic visits are recommended:<\/p>\n
Additional considerations for follow-up care include:<\/p>\n
\u201cWe anticipate that decisions guided by these recommendations will result in more rapid diagnosis and application of effective, evidence-based treatments, leading to better outcomes, such as decreased risk of death and disability, for people with acute pulmonary embolism,\u201d Creager said.<\/p>\n The guideline, led by the American Heart Association and the American College of Cardiology Joint Committee on Clinical Practice Guidelines, was developed in collaboration with and endorsed by eight other health care organizations: the American College of Clinical Pharmacy; the American College of Emergency Physicians; the American College of Chest Physicians; the Society for Cardiovascular Angiography & Interventions; the Society of Hospital Medicine; the Society of Interventional Radiology; the Society for Vascular Medicine; and the Society of Vascular Nursing. American Heart Association\/American College of Cardiology.<\/p>\n Co-authors and members of the guideline writing committee are Co-Vice Chairs Geoffrey D. Barnes, M.D., M.Sc., FAHA, FACC, and Jay Giri, M.D., M.P.H., FAHA, FACC; Debabrata Mukherjee, M.D., M.S., FAHA, FACC; William Schuyler Jones, M.D., FACC; Allison E. Burnett, Pharm.D., Ph.C.; Teresa Carman, M.D.; Ana I. Casanegra, M.D., M.S., FAHA; Lana A. Castellucci, M.D., M.Sc.; Sherrell M. Clark; Mary Cushman, M.D., M.Sc., FAHA; Kerstin de Wit, M.B.Ch.B., M.Sc., M.D.; Jennifer M. Eaves, D.N.P., M.S.N., R.N.; Margaret C. Fang, M.D., M.P.H.; Joshua B. Goldberg, M.D.; Stanislav Henkin, M.D, FAHA, FACC; Hillary Johnston-Cox, M.D., FACC; Sabeeda Kadavath, M.D., FACC; Daniella Kadian-Dodov, M.D., FAHA, FACC; William Brent Keeling, M.D., FACC; Andrew J.P. Klein, M.D., FACC; Jun Li, M.D.; Michael C. McDaniel, M.D., FACC; Lisa K. Moores, M.D.; Gregory Piazza, M.D., M.S., FAHA, FACC; Karen S. Prenger, M.S., A.P.R.N.-C.N.S.; Steven C Pugliese, M.D.; Mona Ranade, M.D; Rachel P. Rosovsky, M.D, M.P.H.; Farla Russo; Eric A. Secemsky, M.D., M.Sc., FAHA, FACC; Akhilesh K. Sista, M.D., FAHA; Leben Tefera, M.D., FACC; Ido Weinberg, M.D., FACC; Lauren M. Westafer, D.O., M.P.H., M.S.; and Michael N. Young, M.D., FACC. Authors\u2019 disclosures are listed in the manuscript.<\/p>\n The Association receives more than 85% of its revenue from sources other than corporations. These sources include contributions from individuals, foundations and estates, as well as investment earnings and revenue from the sale of our educational materials. Corporations (including pharmaceutical, device manufacturers and other companies) also make donations to the Association. The Association has strict policies to prevent any donations from influencing its science content and policy positions. Overall financial information is available\u00a0here<\/a>.<\/p>\n Additional Resources:<\/p>\n
###<\/p>\n About the American Heart Association <\/p>\n The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public\u2019s health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org<\/a>, Facebook<\/a>, X<\/a> or by calling 1-800-AHA-USA1.<\/p>\n About the American College of Cardiology For Media Inquiries: 214-706-1173<\/p>\n American Heart Association: Amanda Ebert: Amanda.Ebert@heart.org<\/a><\/p>\n ACC: Olivia Walther:\u00a0owalther@acc.org<\/a><\/p>\n For Public Inquiries: 1-800-AHA-USA1 (242-8721)<\/p>\n
\n\tMajor surgery or trauma
\n\tHospitalization
\n\tProlonged immobility (such as bed rest or long travel)
\n\tPregnancy and postpartum (within 6 weeks after delivery)
\n\tUse of oral contraceptives or estrogen treatment
\n\tObesity (defined by BMI \u2265 30)
\n\tSmoking
\n\tAtherosclerotic cardiovascular disease<\/a> (heart disease caused by plaque buildup in the arteries)
\n\tCancer
\n\tThrombophilias<\/a> (blood clotting disorders)
\n\tAge (risk increases after age 40)
<\/p>\n
\n\tEarly follow-up: All patients should have a follow-up communication or clinic visit within one week of hospital discharge. This visit should review the treatment plan, confirm patients are taking medications as prescribed and check for bleeding complications.
\n\tAdditional follow-up: A clinic visit should also occur by three months after diagnosis to determine how long anticoagulant therapy will continue, assess the need for further testing and evaluate ongoing symptoms.
\n\tLong\u2011term monitoring: At every visit for at least one year, patients should be screened for symptoms or functional limitations suggestive of chronic thromboembolic pulmonary disease (CTEPD), a condition in which persistent blood clots cause long-term blockage of arteries in the lungs. CTEPD can lead to shortness of breath, fatigue, pulmonary hypertension and right-sided heart failure.
\n\tOngoing anticoagulation review: For patients remaining on anticoagulants beyond 3-6 months, clinicians should periodically reassess the risks and benefits of continued therapy.
<\/p>\n
\n\tPsychological health: Depression, anxiety and post-traumatic stress disorder are common in patients who have had acute PE. Screening for these mental health conditions and evaluation of quality of life are suggested for appropriate management and referral.
\n\tPhysical activity: Once treatment with an anticoagulant for acute PE has begun, walking early in recovery is encouraged to help keep blood flow moving and prevent the body from deconditioning.
\n\tPrecautions for travel: Long-haul (\u22655 hours) travel, whether by car, train or plane, often involves limited mobility, which can increase the risk of another clot. People who have had or are at risk for acute PE should frequently move around, limit long-distance travel and use compression socks or stockings, to reduce the risk of blood clots.
\n\tBirth control\/Pregnancy: Women of childbearing age with acute PE should be counseled about contraception and also about anticoagulation options in the event that they become pregnant. In women with a previous acute PE who become pregnant, their multidisciplinary care team should include obstetricians, and also hematologists, cardiologists or other specialists of PE to help minimize pregnancy-related complications.
<\/p>\n
\n\tMultimedia, including video interview clips with Mark A. Creager, M.D, FAHA, FACC, chair of the guideline writing committee, a graphic of the Acute PE Clinical Categories and more available\u00a0on right column of release link<\/a>.
\n\tAfter Feb. 19, 2026, view the manuscript online in Circulation<\/a> and JACC<\/a>.
\n\tAmerican Heart Association Guideline Hub for Professionals<\/a> (at embargo lift \u2013 2 p.m. ET, Feb. 19, 2026)
\n\tJACC.org Guideline Hub<\/a> (available at 10 a.m. ET, Feb. 23, 2026)
\n\tAcute PE Guideline-at-a-Glance<\/a> (available at 10 a.m. ET, Feb. 23, 2026)
\n\tACC Guideline Clinical App<\/a> (at embargo lift 2 p.m. ET, Feb. 19, 2026)
\n\t\u00b7American Heart Association Scientific Statement: Disparities in Current Pulmonary Embolism Management and Outcomes<\/a> (March 2025)
\n\tAmerican Heart Association \u00a0health initiative: Pulmonary Embolism Quality Improvement Initiative<\/a>
\n\tFollow American Heart Association\/American Stroke Association news on X @HeartNews<\/a>
\n\tFollow the ACC at\u00a0@ACCinTouch<\/a>
\n\tFollow news from the AHA\u2019s flagship journal\u00a0Circulation\u00a0@CircAHA<\/a>
\n\tFollow news from the ACC\u2019s flagship journal JACC @JACCJournals<\/a>
<\/p>\n
\nThe American College of Cardiology (ACC) is the global leader in transforming cardiovascular care and improving heart health for all. As the preeminent source of professional medical education for the entire cardiovascular care team since 1949, ACC credentials cardiovascular professionals in over 140 countries who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. Through its world-renowned family of JACC Journals, NCDR registries, ACC Accreditation Services, global network of Member Sections, CardioSmart patient resources and more, the College is committed to ensuring a world where science, knowledge and innovation optimize patient care and outcomes. Learn more at\u00a0www.ACC.org<\/a>\u00a0or follow\u00a0@ACCinTouch<\/a>.<\/p>\n